Kirkland and Wachtell lead for $74 billion pharma deal
Bristol-Myers Squibb has tapped Kirkland & Ellis to handle antitrust issues stemming from the pharmaceutical company’s $74 billion purchase of Celgene, which has retained Wachtell Lipton Rosen & Katz.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10